8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We investigated the cross-neutralising potential of serum and nasal wash samples from volunteers who were intranasally immunised once with a monovalent replication-deficient delNS1-H1N1 influenza virus vaccine (7.7log10TCID50/volunteer). Eight out of twelve (8/12) vaccinees responded to vaccination with a significant increase of antibody levels in serum IgG ELISA, mucosal IgA ELISA, MNA or HAI. Four responders showed delNS1-specific ELISA IgA increases and revealed excellent homosubtypic neutralising activity in serum and mucosal washings (4/4). However, 0/4 of the sera but 3/4 of the nasal washings neutralised also heterosubtypic H3N2 and H5N1 influenza viruses. Depletion experiments proved that IgA but not IgG is responsible for the cross-neutralising activity of the nasal wash sample. Our findings indicate that the induction of virus-neutralising IgA may represent a valuable correlate of cross-protection of intranasal influenza vaccines and that the delNS1 concept constitutes a promising approach to protect humans from seasonal and pandemic influenza threats.

          Related collections

          Author and article information

          Journal
          Vaccine
          Vaccine
          Elsevier BV
          1873-2518
          0264-410X
          Apr 07 2014
          : 32
          : 17
          Affiliations
          [1 ] AVIR Green Hills Biotechnology AG, Vienna, Austria; University of Natural Resources and Life Sciences, Vienna, Austria.
          [2 ] AVIR Green Hills Biotechnology AG, Vienna, Austria.
          [3 ] AVIR Green Hills Biotechnology AG, Vienna, Austria. Electronic address: efbio6@gmail.com.
          Article
          S0264-410X(14)00182-0
          10.1016/j.vaccine.2014.02.009
          24560674
          9c15e63c-054f-43e1-aaf5-66b5b05c2d5a
          History

          Cross-reactive antibodies,delNS1 influenza virus vaccine,Single intranasal immunisation,Nasal wash IgA,Heterologous immunity

          Comments

          Comment on this article